As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...

Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...

Several recent studies have suggested HRT is a risk factor in various conditions, notably Alzheimer's - now UK boffins have ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

All 16 of Indiana’s designated senior care organizations — known as Area Agencies on Aging — are now required to have a ...

Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests ...

Genetic differences that contribute to how long a person will live and their risk of Alzheimer's disease have been identified ...

The third most common form of dementia is often mistaken for Alzheimer's despite different treatment needsCognitive profiles ...

Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...

This specifically involved distinguishing between Alzheimer's disease, the most common form of dementia, and Lewy body ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...